Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series.

Tzaribachev N, Koetter I, Kuemmerle-Deschner JB, Schedel J.

Cases J. 2009 Aug 6;2:6609. doi: 10.1186/1757-1626-0002-0000006609.

2.

B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.

Kumar S, Benseler SM, Kirby-Allen M, Silverman ED.

Pediatrics. 2009 Jan;123(1):e159-63. doi: 10.1542/peds.2008-2361. Epub 2008 Dec 15.

PMID:
19074962
3.

Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.

El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP.

J Pediatr. 2007 Apr;150(4):376-82.

PMID:
17382113
4.

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.

Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M, Graillet D, Gonzalez L, Rojas-Rodriguez J, Pineda-Almazana A, Zamudio-Huerta L, Lopez-Colombo A.

Lupus. 2010 Feb;19(2):213-9. doi: 10.1177/0961203309351541. Epub 2009 Dec 4.

PMID:
19965944
5.

B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.

Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D.

Clin Otolaryngol. 2009 Aug;34(4):328-35. doi: 10.1111/j.1749-4486.2009.01968.x.

PMID:
19673980
6.

Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations.

Seo P, Specks U, Keogh KA.

J Rheumatol. 2008 Oct;35(10):2017-23. Epub 2008 Aug 1.

PMID:
18688911
7.

Rituximab therapy for childhood-onset systemic lupus erythematosus.

Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, Deschênes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B; French Pediatric-Onset SLE Study Group.

J Pediatr. 2006 May;148(5):623-627. Erratum in: J Pediatr. 2006 Oct;149(4):586.

PMID:
16737873
8.
9.
10.

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X; Club Rheumatismes et Inflammation (CRI).

Ann Rheum Dis. 2005 Jun;64(6):913-20. Epub 2004 Nov 18.

11.

[Cyclophosphamide pulse therapy for refractory rheumatic diseases].

Tateishi M, Taniguchi A, Moriguchi M, Hara M, Kashiwazaki S.

Nihon Rinsho Meneki Gakkai Kaishi. 1997 Jun;20(3):152-8. Japanese.

PMID:
9256607
12.

Two cases of refractory Wegener's granulomatosis successfully treated with rituximab.

Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata M, Morimoto S, Kaneda K, Kobayashi S, Hashimoto H, Takasaki Y.

Intern Med. 2007;46(7):409-14. Epub 2007 Apr 2.

13.

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.

Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harlé JR, Hot A, Kahn JE, Lambotte O, Larroche C, Léone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE; Club Rhumatismes et Inflammation.

Arthritis Rheum. 2010 Aug;62(8):2458-66. doi: 10.1002/art.27541.

14.

Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.

Pan D, Moskowitz CH, Zelenetz AD, Straus D, Kewalaramani T, Noy A, Qin J, Teruya-Feldstein J, Portlock CS.

Cancer J. 2002 Sep-Oct;8(5):371-6.

PMID:
12416894
15.

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.

Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, Tanaka Y.

Rheumatology (Oxford). 2005 Feb;44(2):176-82. Epub 2004 Oct 19.

PMID:
15494350
16.

Immunoablation followed by autologous hematopoietic stem cell infusion for the treatment of severe autoimmune disease.

Rabusin M, Andolina M, Maximova N, Lepore L, Parco S, Tuveri G, Jankovic G.

Haematologica. 2000 Nov;85(11 Suppl):81-5.

PMID:
11268330
17.

Refractory Wegener's granulomatosis: a model for shorter immunotherapy of autoimmune diseases.

Lockwood CM.

J R Coll Physicians Lond. 1998 Sep-Oct;32(5):473-8.

PMID:
9819743
18.

[Efficacy of rituximab in a case of refractory bullous pemphigoid].

Reguiaï Z, Tchen T, Perceau G, Bernard P.

Ann Dermatol Venereol. 2009 May;136(5):431-4. doi: 10.1016/j.annder.2008.10.038. Epub 2009 Feb 26. French.

PMID:
19442800
19.

Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation.

Euler HH, Marmont AM, Bacigalupo A, Fastenrath S, Dreger P, Hoffknecht M, Zander AR, Schalke B, Hahn U, Haas R, Schmitz N.

Blood. 1996 Nov 1;88(9):3621-5.

20.

High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.

Petri M, Jones RJ, Brodsky RA.

Arthritis Rheum. 2003 Jan;48(1):166-73.

Supplemental Content

Support Center